{"id":63148,"date":"2026-04-14T22:51:37","date_gmt":"2026-04-14T14:51:37","guid":{"rendered":"https:\/\/flcube.com\/?p=63148"},"modified":"2026-04-14T22:51:38","modified_gmt":"2026-04-14T14:51:38","slug":"curegenes-cg-0255-receives-nmpa-approval-for-ischemic-stroke-trial-first-thiol-based-p2y12-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63148","title":{"rendered":"CureGene&#8217;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor"},"content":{"rendered":"\n<p><strong>Shanghai CureGene Pharmaceutical Co., Ltd<\/strong> announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a study of its <strong>Category 1 innovative drug CG-0255<\/strong> for the treatment of <strong>ischemic stroke<\/strong>. The next-generation antiplatelet agent represents the <strong>world&#8217;s first P2Y12 receptor inhibitor<\/strong> based on a <strong>thiol-based prodrug design<\/strong>, available in both <strong>intravenous and oral formulations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai CureGene Pharmaceutical Co., Ltd<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 innovative drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Ischemic stroke<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical trial approval granted<\/td><\/tr><tr><td><strong>Molecular Innovation<\/strong><\/td><td>First thiol-based P2Y12 receptor inhibitor globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-technological-innovation\">Drug Profile &amp; Technological Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> P2Y12 receptor inhibition with novel thiol-based prodrug design<\/li>\n\n\n\n<li><strong>Dual Formulations:<\/strong> Available as both intravenous (acute setting) and oral (maintenance therapy) preparations<\/li>\n\n\n\n<li><strong>Metabolic Advantage:<\/strong> Single-step hydrolysis directly releases active metabolite, bypassing CYP2C19 metabolic pathway<\/li>\n\n\n\n<li><strong>Clopidogrel Resistance Solution:<\/strong> Fundamentally overcomes &#8220;clopidogrel resistance&#8221; caused by CYP2C19 enzyme deficiency affecting 30-50% of Asian populations<\/li>\n\n\n\n<li><strong>Key Advantages:<\/strong><\/li>\n\n\n\n<li>Rapid onset of action<\/li>\n\n\n\n<li>Strong antiplatelet efficacy<\/li>\n\n\n\n<li>Low inter-patient variability<\/li>\n\n\n\n<li>Minimal drug-drug interaction risk<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-significance\">Clinical Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-addressing-unmet-need\">Addressing Unmet Need<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ischemic Stroke Burden:<\/strong> China experiences approximately 2.5 million new ischemic stroke cases annually<\/li>\n\n\n\n<li><strong>Current Limitations:<\/strong> Standard antiplatelet therapies show variable response rates due to genetic polymorphisms<\/li>\n\n\n\n<li><strong>CYP2C19 Challenge:<\/strong> High prevalence of loss-of-function alleles in Asian populations reduces clopidogrel effectiveness<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Need for reliable, predictable antiplatelet therapy in acute stroke management<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Status:<\/strong> World&#8217;s first thiol-based P2Y12 inhibitor with dual IV\/oral availability<\/li>\n\n\n\n<li><strong>Pharmacokinetic Superiority:<\/strong> Predictable metabolism independent of genetic variations<\/li>\n\n\n\n<li><strong>Clinical Flexibility:<\/strong> Seamless transition from IV to oral therapy in hospital-to-home care continuum<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Reduced bleeding risk through consistent, controlled antiplatelet effect<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Antiplatelet Market:<\/strong> Valued at RMB 8 billion ($1.2 billion) annually with premium pricing potential for superior agents<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Technology platform applicable to other indications requiring antiplatelet therapy<\/li>\n\n\n\n<li><strong>Reimbursement Positioning:<\/strong> Category 1 innovative drug status supports favorable NRDL negotiation position<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Novel mechanism provides foundation for global intellectual property protection<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-strategy\">Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initial Focus:<\/strong> Ischemic stroke indication with high unmet need and clear regulatory pathway<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Potential evaluation in acute coronary syndrome, peripheral artery disease, and other thrombotic conditions<\/li>\n\n\n\n<li><strong>Combination Therapy:<\/strong> Opportunities for use with other stroke therapeutics including thrombolytics<\/li>\n\n\n\n<li><strong>Manufacturing Readiness:<\/strong> Dual formulation development demonstrates advanced pharmaceutical capabilities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>CureGene will now initiate patient enrollment in the Phase I\/II clinical trial, focusing on safety, tolerability, and preliminary efficacy endpoints. The company plans to leverage China&#8217;s expedited review pathways for innovative drugs addressing critical unmet medical needs.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations for CG-0255. Actual results may differ due to risks inherent in pharmaceutical development including clinical trial outcomes, regulatory approvals, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63150,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1575],"class_list":["post-63148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-curegene-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CureGene&#039;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world&#039;s first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63148\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CureGene&#039;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world&#039;s first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63148\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T14:51:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T14:51:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CureGene&#8217;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor\",\"datePublished\":\"2026-04-14T14:51:37+00:00\",\"dateModified\":\"2026-04-14T14:51:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1406.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CureGene Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63148#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63148\",\"name\":\"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1406.webp\",\"datePublished\":\"2026-04-14T14:51:37+00:00\",\"dateModified\":\"2026-04-14T14:51:38+00:00\",\"description\":\"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63148\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1406.webp\",\"width\":1080,\"height\":608,\"caption\":\"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63148#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CureGene&#8217;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63148","og_locale":"en_US","og_type":"article","og_title":"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor","og_description":"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","og_url":"https:\/\/flcube.com\/?p=63148","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T14:51:37+00:00","article_modified_time":"2026-04-14T14:51:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63148#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63148"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CureGene&#8217;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor","datePublished":"2026-04-14T14:51:37+00:00","dateModified":"2026-04-14T14:51:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63148"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63148#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","keywords":["Clinical trial approval \/ initiation","CureGene Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63148#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63148","url":"https:\/\/flcube.com\/?p=63148","name":"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63148#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63148#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","datePublished":"2026-04-14T14:51:37+00:00","dateModified":"2026-04-14T14:51:38+00:00","description":"Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) to initiate a study of its Category 1 innovative drug CG-0255 for the treatment of ischemic stroke. The next-generation antiplatelet agent represents the world's first P2Y12 receptor inhibitor based on a thiol-based prodrug design, available in both intravenous and oral formulations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63148#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63148"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63148#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","width":1080,"height":608,"caption":"CureGene's CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63148#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CureGene&#8217;s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial \u2013 First Thiol-Based P2Y12 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63148"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63148\/revisions"}],"predecessor-version":[{"id":63151,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63148\/revisions\/63151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63150"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}